Soleno Therapeutics, Inc. Notice of May 5, 2026 Deadline for Class Action Lawsuit

•

Kahn Swick, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana Charles C. Foti, Jr., notified investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.

The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were allegedly adversely affected by securities fraud between March 26, 2025 and November 4, 2025.

Allegations in the Complaint

According to the Complaint, Soleno and certain of its executives are charged with failing to disclose material information during the Class Period, in violation of federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, the following:

The Phase 3 clinical trial program for DCCR, the Company’s only commercial product for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome (“PWS”), allegedly minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its administration, including indications of excessive fluid retention among clinical trial participants.
As a result, the administration of DCCR to treat hyperphagia in individuals with PWS allegedly posed materially greater safety risks than disclosed by the Company.
Consequently, DCCR allegedly had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

Case Information

The case is City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979.

Lead Plaintiff Deadline

Investors who invested in Soleno and suffered a loss during the relevant time frame have until May 5, 2026 to request that the Court appoint them as lead plaintiff. The notice states that the ability to share in any recovery does not require serving as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF is a boutique securities litigation law firm. The firm states that its partners include former Louisiana Attorney General Charles C. Foti, Jr. It also states that, in the past year, it was ranked by SCAS among the top 10 firms nationally based on total settlement value. KSF states it serves public and private institutional investors and retail investors seeking recoveries for investment losses related to corporate fraud or malfeasance by publicly traded companies. The firm lists offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.